Rute Castro has extensive experience in the field of biochemistry and microbial physiology, currently serving as a Researcher at the Biopilot Plant at iBET - Instituto de Biologia Experimental e Tecnológica since January 2015. Prior to this role, Rute Castro held a post-doctoral position at IBET from March 2010 to December 2014 and completed a PhD at ITQB-UNL from 2005 to 2009. Rute Castro earned a Doctorate in Biochemistry/Microbial Physiology from Instituto de Tecnologia Química e Biológica, UNL, from 2003 to 2009, and holds a Graduate degree in Biological Engineering from Instituto Superior Técnico, obtained between 1997 and 2002.
This person is not in the org chart
iBET - Instituto de Biologia Experimental e Tecnológica
iBET is a private non-profit research institution specialized in biotechnology research and bioprocess development. iBET acts as an interface between academia and industry while also creating and organizing autonomous knowledge. Our expertise includes the development of bioprocesses for complex biopharmaceuticals and advanced therapies, including vaccines, recombinant proteins, and viral vectors for gene and onco- therapy, stem cells for cell therapy applications; development of in-vitro cell models and protocols for pre-clinical research; analytical tools for quality control of biologics; and structural biology for assisted drug design. Within Food and Health, we develop new solutions for the detection of food frauds, food and water-borne pathogens, and work on the discovery of new bioactive food supplements. To address some environmental issues, we also develop new sustainable, energy saving, processes for both food and water industries. iBET’s infrastructure comprises more than 20 R&D laboratories, a GMP certified Analytical Services Unit, a Mass Spectrometry Unit and a Late-Stage R&D and Bioproduction Unit (2000m2). The new iBET Biofarma building added 29 laboratories to its research and analytical platform infrastructure, including one BLS3 Lab. As an R&D institution, iBET has coordinated over 30 international projects and participated as work-package leader in more than 100 EU-funded projects. iBET has also been involved in some of the most prestigious RD&I and technology transfer projects, with remarkable international impact and has several well established collaborations in Networks of Excellence and with international pharmaceutical companies, such as Bayer, Novartis, Merck, Abbvie, Sanofi, Apceth, AstraZeneca, Glaxo-Smith-Kline , Merck & Co., among others. iBET’s success relies heavily on its large staff of over 250 people, of which about 110 have a PhD degree, and who contribute with advanced skills and experience to our areas of expertise.